Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic Anemia
Régis Peffault de Latour(Hôpital Saint-Louis), Gèrard Socié(Hôpital Saint-Louis), Éric Deconinck(European Union), Mohamad Mohty(Sorbonne Université), Marlène Pasquet(Centre Hospitalier Universitaire de Toulouse), Felipe Suárez(Hôpital Necker-Enfants Malades), Thierry Lamy(Centre Hospitalier Universitaire de Lille), Fiorenza Barraco(Hôpital Lyon Sud), Jean‐Yves Cahn, Charlotte Jubert(Centre Hospitalier Universitaire de Bordeaux), Reza Tabrizi(Université de Bordeaux), Stéphanie Nguyen(Sorbonne Université), Jacques‐Olivier Bay(Centre Hospitalier Universitaire de Clermont-Ferrand), Thorsten Brawn(Délégation Paris 7), Claire Galambrun(Hôpital de la Timone), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 0
Related Papers
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968